Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy
Cancer therapy has been revolutionized by immune checkpoint inhibitors (ICIs) that create a new paradigm among cancer immunotherapies. These agents restore the immune system capacity to fight cancer through blocking the action of major immune checkpoint proteins that suppress immune responses such a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523325001767 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849433424055500800 |
|---|---|
| author | Zeinab Dalloul Jana Grenel Briend Mariama Diawara Catherine Taylor Rodney J. Ouellette |
| author_facet | Zeinab Dalloul Jana Grenel Briend Mariama Diawara Catherine Taylor Rodney J. Ouellette |
| author_sort | Zeinab Dalloul |
| collection | DOAJ |
| description | Cancer therapy has been revolutionized by immune checkpoint inhibitors (ICIs) that create a new paradigm among cancer immunotherapies. These agents restore the immune system capacity to fight cancer through blocking the action of major immune checkpoint proteins that suppress immune responses such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which tumors exploit for immune escape. Another advancement is the absence of known biomarkers involves ICIs, which can further be translated into new liquid tests like liquid biopsies, indicating the immune status of the patient. Liquid biopsy is a minimally invasive method for identifying tumor-derived components such as circulating tumor cells, cell-free DNA and extracellular vesicles (EVs) from body fluids for analysis. Researchers increasingly use liquid biopsy for biomarkers discovery and patient stratification into clinical applications. Even though immunotherapy has great advances, still there are obstacles faced while using ICIs. Many patients fail to respond to the treatment because of the heterogeneous mechanisms of resistance. Immunotherapy resistance is a dynamic interplay between tumors and their surrounding stroma. To understand this variability, humanized mice models are increasingly used for mirroring human immune responses. Such models offer insight into cancer immunotherapy when human immune system is engrafted into mice, and EV and biomarker profiles are established in those models. EVs reflect differences in tumor characteristics and the immune landscape around tumors to develop personalized strategies to enhance ICI efficacy. This may improve patient prognosis, giving reason to hope for better, more effective treatments. |
| format | Article |
| id | doaj-art-45a958b5ba64437fa5ddcbad8c5bbd6b |
| institution | Kabale University |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-45a958b5ba64437fa5ddcbad8c5bbd6b2025-08-20T03:27:02ZengElsevierTranslational Oncology1936-52332025-09-015910244510.1016/j.tranon.2025.102445Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapyZeinab Dalloul0Jana Grenel Briend1Mariama Diawara2Catherine Taylor3Rodney J. Ouellette4Atlantic Cancer Research Institute, Moncton, New Brunswick, CanadaAtlantic Cancer Research Institute, Moncton, New Brunswick, CanadaAtlantic Cancer Research Institute, Moncton, New Brunswick, CanadaAtlantic Cancer Research Institute, Moncton, New Brunswick, CanadaAtlantic Cancer Research Institute, Moncton, New Brunswick, Canada; Department of Chemistry and Biochemistry, Université de Moncton, Moncton, New Brunswick, Canada; Dr Georges L. Dumont University Hospital, Vitalite Health Network, Moncton, New Brunswick, Canada; Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada; Corresponding author.Cancer therapy has been revolutionized by immune checkpoint inhibitors (ICIs) that create a new paradigm among cancer immunotherapies. These agents restore the immune system capacity to fight cancer through blocking the action of major immune checkpoint proteins that suppress immune responses such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which tumors exploit for immune escape. Another advancement is the absence of known biomarkers involves ICIs, which can further be translated into new liquid tests like liquid biopsies, indicating the immune status of the patient. Liquid biopsy is a minimally invasive method for identifying tumor-derived components such as circulating tumor cells, cell-free DNA and extracellular vesicles (EVs) from body fluids for analysis. Researchers increasingly use liquid biopsy for biomarkers discovery and patient stratification into clinical applications. Even though immunotherapy has great advances, still there are obstacles faced while using ICIs. Many patients fail to respond to the treatment because of the heterogeneous mechanisms of resistance. Immunotherapy resistance is a dynamic interplay between tumors and their surrounding stroma. To understand this variability, humanized mice models are increasingly used for mirroring human immune responses. Such models offer insight into cancer immunotherapy when human immune system is engrafted into mice, and EV and biomarker profiles are established in those models. EVs reflect differences in tumor characteristics and the immune landscape around tumors to develop personalized strategies to enhance ICI efficacy. This may improve patient prognosis, giving reason to hope for better, more effective treatments.http://www.sciencedirect.com/science/article/pii/S1936523325001767Liquid biopsyImmunotherapyImmune checkpoint inhibitorsExtracellular vesiclesBiomarkersResistance |
| spellingShingle | Zeinab Dalloul Jana Grenel Briend Mariama Diawara Catherine Taylor Rodney J. Ouellette Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy Translational Oncology Liquid biopsy Immunotherapy Immune checkpoint inhibitors Extracellular vesicles Biomarkers Resistance |
| title | Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy |
| title_full | Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy |
| title_fullStr | Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy |
| title_full_unstemmed | Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy |
| title_short | Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy |
| title_sort | leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy |
| topic | Liquid biopsy Immunotherapy Immune checkpoint inhibitors Extracellular vesicles Biomarkers Resistance |
| url | http://www.sciencedirect.com/science/article/pii/S1936523325001767 |
| work_keys_str_mv | AT zeinabdalloul leveragingliquidbiopsytouncoverresistancemechanismsandguidepersonalizedimmunotherapy AT janagrenelbriend leveragingliquidbiopsytouncoverresistancemechanismsandguidepersonalizedimmunotherapy AT mariamadiawara leveragingliquidbiopsytouncoverresistancemechanismsandguidepersonalizedimmunotherapy AT catherinetaylor leveragingliquidbiopsytouncoverresistancemechanismsandguidepersonalizedimmunotherapy AT rodneyjouellette leveragingliquidbiopsytouncoverresistancemechanismsandguidepersonalizedimmunotherapy |